A study sponsored by Cyberonics Inc., Houston, TX, shows that patients with treatment-resistant depression are very costly to the healthcare system due to extremely high use of both depression-related and general medical services. The study analyzed medical and prescription claims data from the 1995-1998 MEDSTAT MarketScan® Databases to evaluate healthcare utilization and costs of patients with treatment-resistant depression.
A study sponsored by Cyberonics Inc., Houston, TX, shows that patients with treatment-resistant depression are very costly to the healthcare system due to extremely high use of both depression-related and general medical services. The study analyzed medical and prescription claims data from the 1995-1998 MEDSTAT MarketScan® Databases to evaluate healthcare utilization and costs of patients with treatment-resistant depression.
The study found that treatment-resistant depression was associated with higher inpatient, outpatient and total healthcare costs. Specifically, average total annual healthcare costs for patients with low-to-moderate treatment-resistant depression were $9,191, compared with $41,475 for those with severe treatment-resistant depression. Treatment-resistant patients were twice as likely to be hospitalized, and they had 15% more outpatient visits than the non-treatment-resistant depressed group. Treatment resistance was associated with two to three times more psychotropic medication use in addition to antidepressant medications. Treatment-resistant patients were also more likely to be diagnosed with bipolar disorders, co-morbid anxiety and substance-related disorders.
Said Ernst Berndt of the Massachusetts Institute of Technology: "These results provide strong evidence that treatment-resistant depression generates huge costs for the healthcare system, and underscore the need to find effective, tolerable, long-term treatment options for this patient population." PR
FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk
February 18th 2025Ospomyv, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Xbryk, a biosimilar to Xgeva, is indicated for preventing skeletal-related events in multiple myeloma and solid tumor bone metastases.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.